A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer

2020122 citationsJournal Articlegreen Open Access

Authors

Annie A. Wu · Johns Hopkins University

Katherine M. Bever · Johns Hopkins University

Won Jin Ho · Johns Hopkins University

Elana J. Fertig · Johns Hopkins University

Nan Niu · Johns Hopkins University

Lei Zheng · Johns Hopkins University

Rose Parkinson ·

Abstract

GVAX and ipilimumab maintenance therapy did not improve OS over continuation of chemotherapy and resulted in a numerically inferior survival in metastatic PDA. However, clinical responses and biological effects on immune cells were observed. Further study of novel combinations in the maintenance treatment of metastatic PDA is feasible.

Topics & Keywords

Cancer Research and Treatments Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 26, Issue 19, pp. 5129-5139

DOI: 10.1158/1078-0432.ccr-20-1025

Field-Weighted Citation Impact: 9.51